The targets, acquired from CytoHubba algorithms and literatures' supplement (NOS2, NOS3, ICAM1, PLA2G2A, SERPINE, and ESR1) [36–39], were regarded as core targets of SMYAD for treating AAA. Here, ICAM1 is linked to triple-A syndrome.